Rocket Pharmaceuticals, Inc.
RP-A501
Danon disease
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for RP-A501 in Danon disease are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“Dosing of additional patients for the Phase 2 study of RP-A501 for Danon disease anticipated in the first half of 2026.”